" class="no-js "lang="en-US"> Brook Blackmore - Medtech Alert
Friday, September 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Brook Blackmore

Brook Blackmore

About Brook Blackmore

Brook Blackmore is the Vice President, Clinical Operations of Azra AI. She previously worked at Thyme Care as a Vice President Clinical Operations. Brook Blackmore attended Belmont University.

Related Story

Artificial Intelligence

 Azra AI Expands Innovative Incidental Findings Technology to Help Clinicians Identify More Cancers | Pharmtech Focus

Azra AI Expands Innovative Incidental Findings Technology to Help Clinicians Identify More Cancers

July 7 2022

Azra AI‘s proprietary software — which uses artificial intelligence (AI) and natural language processing to […]